Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Revolution Medicines Inc. Common Stock (RVMD) vs Trip.com Group Ltd (TCOM) Price & Performance

Revolution Medicines Inc. Common StockTrade
Trip.com Group LtdTrade

Price performance (Past 24H)

Key statistics

Revolution Medicines Inc. Common Stock vs Trip.com Group Ltd — how do they compare? Revolution Medicines Inc. Common Stock trades at $189.1 (market cap $40.32B), while Trip.com Group Ltd trades at $38.66 (market cap $23.75B). The key difference: Revolution Medicines Inc. Common Stock is the larger of the two by market cap, and Trip.com Group Ltd pays a 0.42% dividend while Revolution Medicines Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Revolution Medicines Inc. Common Stock for 0 Days and Trip.com Group Ltd for 79 Days on average.

RVMDTCOM
Market Cap
$40.32B$23.75B
Volume
4,855,7342,089,737
Sector
HealthConsumer Cyclical
52-Week High
$221.15$78.96
52-Week Low
$47.50$37.96
Typical Hold Time
0 Days79 Days
Enterprise Value
$37.02B$15.91B
Dividend Yield
—0.42%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Revolution Medicines Inc. Common Stock

No Aura AI signal available yet.

Trip.com Group Ltd

Trip.com Group (TCOM) trades at $38.09, down 0.44% on the day, with technical indicators showing bearish momentum despite oversold RSI readings. The company demonstrates strong fundamentals with revenue growth from $53.3B in 2024 to $62.4B in 2025 and robust net income margins of 36.9%. Recent Q2 2026 earnings beat expectations with $1.07 EPS versus $0.98 expected, though regulatory headwinds from Chinese antitrust actions create uncertainty.

The investment outlook remains positive given attractive valuations (P/E 7.36, EV/EBITDA 3.55) and analyst consensus price target of $56.64 representing 49% upside. However, regulatory risks and competitive pressures from dismantled ranking algorithms require monitoring. With 70% analyst buy ratings and strong cash flow generation, TCOM offers value for patient investors despite near-term technical weakness.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

RVMD
100% Buy0% Sell
Avg holding period · 0 Days
TCOM
100% Buy0% Sell
Avg holding period · 79 Days

About Revolution Medicines Inc. Common Stock

Revolution Medicines develops precision medicines for cancer. Its programs focus on targeting RAS-driven cancers and related signaling pathways.

Read more on RVMD →

About Trip.com Group Ltd

Trip.com is the largest online travel agent in China and is positioned to benefit from the country's rising demand for higher-margin outbound travel as passport penetration is only 12% in China. The company generated about 78% of sales from accommodation reservations and transportation ticketing in 2020. The rest of revenue comes from package tours and corporate travel. Prior to the pandemic in 2019, the company generated 25% of revenue from international business, which is important to its margin expansion. Most of sales come from websites and mobile platforms, while the rest come from call centers. The competes in a crowded OTA industry in China, including Meituan, Alibaba-backed Fliggy, Toncheng, and Qunar. The company was founded in 1999 and listed on the Nasdaq in December 2003.

Read more on TCOM →